INS and Hypoglycemia: The effective use of insulin requires a sensitive balance between achieving and maintaining glycaemic targets while limiting the risk of hypoglycaemia.1 Consequently, the assessment and regulatory approval of insulins have depended largely on evidence of glycaemic efficacy combined with incremental reductions in therapy‐induced hypoglycaemia, utilizing data commonly derived from randomized controlled trials (RCTs).7